Paclitaxel is one of the classic three generation chemotherapy drugs,but its water solubility is poor and it needs to be dissolved with organic solvents.Albumin-bound paclitaxel uses nanotechnology to increase drug delivery and bioavailability of paclitaxel with the help of natural albumin.This not only avoids the hypersensitivity/toxicity reaction caused by organic solvents,but also does not require hormone pretreatment;It can also make albumin carry paclitaxel out of the blood circulation more quickly,pass through endothelial cells through receptor mediated endocytosis,and enrich more in tumor tissues through the high permeability and retention effect(EPR effect)of tumors,which continues to show pharmacokinetic advantages.
In the era of immunotherapy,the efficacy of single drug is not enough,and the objective remission rate(ORR)of single drug does not exceed 20%;How to expand the beneficiaries of immunotherapy,combined therapy may be an effective solution,among which the mode of combined chemotherapy is the hot spot of current exploration.
From this perspective,Albumin-bound paclitaxel has its own advantages,its ORR is higher,it can kill tumor cells more effectively,and promote the exposure of tumor antigen;No hormone pretreatment is needed to avoid immunosuppression;Higher tumor tissue enrichment reduces damage to normal tissues.
Note:The potential efficacy and applications introduced in this article are all from published literature.
Yunnan Hande Biotechnology Co.,Ltd has been specializing in the production of paclitaxel API for more than 20 years,and is one of the world’s independent manufacturers of paclitaxel API,a plant-derived anti-cancer drug,approved by the US FDA,European EDQM,Australian TGA,Chinese CFDA,India,Japan and other national regulatory agencies.Hande can provide not only high-quality paclitaxel raw materials,but also technical upgrade services related to paclitaxel formulation.For more information,please feel free to contact us at 18187887160.
Post time: Dec-29-2022